- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05457114
Association Between the Use of Pulmonary Artery Catheter and Clinical Outcomes After Liver Transplantation
The investigators attempted to evaluate whether the use of PAC is associated with better clinical outcomes after liver transplantation compared with the case without PAC.
Study Overview
Status
Detailed Description
Pulmonary artery catheter (PAC) has been used for advanced hemodynamic monitoring during liver transplantation. However, recent advances in less invasive monitoring could provide continuous cardiac output monitoring by arterial waveform analysis. Using this technology, stroke volume variation (SVV) is monitored as a preload index. Calculated systemic vascular resistance (SVR) can be monitored if central venous pressure (CVP) is provided. Therefore, this less invasive form of hemodynamic monitoring may replace the PAC. The investigators attempted to evaluate whether the use of PAC is associated with better clinical outcomes after liver transplantation compared with the case without PAC.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Seoul, South Korea, 03080
- Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients received liver transplantation surgery in a single tertiary care university hospital
Description
Inclusion Criteria:
- Adult patients who underwent living or deceased donor liver transplantation at our tertiary care university hospital between 2006 and 2022
Exclusion Criteria:
- Patients with baseline renal dysfunction
- Missing baseline or outcome variables
- Retransplantation
- Patients who received intraoperative transesophageal echocardiography (TEE) monitoring
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: RETROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Pulmonary artery catheter group
Patients who received pulmonary artery catheter insertion and hemodynamic monitoring by PAC-derived parameters |
PAC was inserted and connected to a continuous cardiac output monitor (Vigilance I from 2006 to 2012; Vigilance II from 2012 to 2022, Edward Lifesciences, Irvine, USA) |
|
Non-pulmonary artery catheter group
Patients who did not received pulmonary artery catheter insertion and were monitored with Flo-Trac FloTrac Vigileo |
Without PAC, monitoring with FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA) was performed for continuous cardiac output monitoring. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants with acute kidney injury
Time Frame: the first 7 postoperative days
|
Acute kidney injury (AKI) was defined by the Kidney Disease Improving Global Outcomes (KDIGO) criteria, which was defined according to the greatest change in serum creatinine level during the postoperative seven days (Stage 1: more than 1.5-fold; stage 2: more than 2-fold; stage 3: more than 3-fold increase from baseline level or increase in serum creatinine to ≥ 4.0 mg/dL or the initiation of renal replacement therapy). The most recent serum creatinine level measured before surgery was collected as a baseline value. |
the first 7 postoperative days
|
|
Number of Participants with early allograft dysfunction
Time Frame: the first 7 postoperative days
|
Early allograft dysfunction (EAD) was defined when one or more of the following are present within the first 7 postoperative days: total bilirubin ≥ 10 mg/dL, prothrombin time: international normalized ratio ≥ 1.6, or aspartate or alanine transaminase > 2000 IU/L |
the first 7 postoperative days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
In-hospital mortality
Time Frame: the first month after admission
|
all-cause mortality during hospitalization |
the first month after admission
|
|
One-year mortality
Time Frame: one year after transplantation
|
all-cause mortality during one year after transplantation |
one year after transplantation
|
|
Length of hospital stay
Time Frame: the first month after admission
|
Length of hospital stay after transplantation |
the first month after admission
|
|
Length of intensive care unit (ICU) stay
Time Frame: the first month after admission
|
Length of intensive care unit stay after transplantation |
the first month after admission
|
Collaborators and Investigators
Investigators
- Study Chair: Won Ho Kim, MD, PhD, Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-2205-117-1327
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.